155 results about "Animal gene" patented technology

Methods are provided for modulating the expression of genes involved in lipid metabolism, useful in the treatment of conditions associated with cardiovascular risk. Antisense oligonucleotides targeted to apolipoprotein B reduce the level of apolipoprotein B mRNA, lower serum cholesterol and shift liver gene expression profiles from those of an obese animal towards those of a lean animal. Further provided are methods for improving the cardiovascular risk of a subject through antisense inhibition of apolipoprotein B. Also provided are methods for employing antisense oligonucleotides targeted to apolipoprotein B to modulate a cellular pathway or metabolic process.

Disclosed is a method of down-regulating the expression of a gene in an animal, wherein a pharmacological formulation comprising a chimeric oligonucleotide complementary to the gene is orally administered to an animal. The oligonucleotide administered has at least one phosphorothioate internucleotide linkage and at least one alkylphosphonate, phosphorodithioate, alkylphosphonothioate, phosphoramidate, phosphoramidite, phosphate ester, carbamate, carbonate, phosphate triester, acetamidate, or carboxymethyl ester internucleotide linkage.

The invention relates to a construction method and application of an immunodeficient mouse animal model, belonging to the field of animal gene engineering and genetic modification. Il2rg gene knockout mice can be obtained by using a CRISPR/Cas9 technology; the Il2rg gene knockout mice have an immunodeficient phenotype. The construction method can be widely applied to multiple fields such as humanized animal models as well as stem cell and tumor research.

Disclosed are capsid-modified rAAV expression vectors, as well as infectious virions, compositions, and pharmaceutical formulations that include them. Also disclosed are methods of preparing and using novel capsid-protein-mutated rAAV vector constructs in a variety of diagnostic and therapeutic applications including, inter alia, as delivery agents for diagnosis, treatment, or amelioration of one or more symptoms of disease or abnormal conditions via in situ and/or ex vivo mammalian gene therapy methods. Also disclosed are large-scale production methods for capsid-modified rAAV expression vectors, viral particles, and infectious virions having improved transduction efficiencies over those of the corresponding, un-modified, rAAV vectors, as well as use of the disclosed compositions in the manufacture of medicaments for a variety of in vitro and/or in vivo applications.

The invention belongs to the technical field of animal gene engineering, relating to clone of cattle longisimus dorsi tenderness related CAPN1 gene segment and an application thereof in cattle marker assisting selection. The obtained CAPN1 gene segment has the nucleotide sequence length of 520bp and comprises full fourteenth exons. A base mutation from A to G exists at the 166bp of the segment, which results in the generation of PsuI-RFLP restriction enzyme polymorphism. The mutation site is taken as a molecular marker, the restriction enzyme PsuI is used for detecting the mutation site, and association analysis can be carried out on the detection result and the cattle longisimus dorsi tenderness. Analysis result shows that striking difference exists among the longisimus dorsi tenderness of different genotype individuals, thus providing a theoretical basis for the seed selection and breeding of cattle. The invention is characterized by obtaining the CAPN1 gene part segment related to the cattle longisimus dorsi tenderness and providing the molecular marker and the application for the marker assisting selection of cattle by using a PCR-RFLP method to carry out polymorphism analysis on the segment.

The present invention relates to methods of making RNAi libraries using E. coli RNAse III for inhibition of mammalian gene expression.

The invention belongs to the field of animal gene engineering, and in particular relates to a synthetic fusion gene for expressing mycoplasma hyopneumoniae and application. The fusion gene is characterized in that a mycoplasma hyopneumoniae P97R1 gene is connected in series with a P36 gene through a Linker, the termination codon of the P36 gene is deleted, the P46 gene with signal peptide removed is fused at the C end of the P36 gene through Linker, and then the fusion gene P97R1-P36-P46 is obtained, wherein the nucleotide sequence of the fusion gene is shown as SEQ ID NO: 1. The fusion gene is included in a prokaryotic expression plasmid, and escherichia coli BL21/pET30a-P97R1-Linker-P36-Linker-P46 containing the plasmid is collected in CCTCC with the collection number CCTCC NO: M2014269. The invention further discloses immune efficacy evaluation of the fusion gene and application of the fusion gene in a novel vaccine.

The invention belongs to the technical field of animal genetic engineering, and particularly relates to a growth hormone receptor gene taken as a Chinese grassland red bull excellent slaughter trait molecular marker and an application thereof. The length of a nucleotide sequence of an obtained GHR genetic segment is 489bp and the nucleotide sequence is a part of an exon. A base mutation exists at a 289-position basic group to cause the generation of restrictive fragment length polymorphism. The mutant site is taken as the molecular marker and detected by a PCR-RFLP (polymerase chain reaction-restrictive fragment length polymorphism) method using restriction enzyme BstACI, and detection results are associated with the Chinese grassland red bull slaughter traits so as to provide theoretical basis for selection breeding of Chinese grassland red bull. The invention is characterized in that partial segment of GHR gene associated with the Chinese grassland red bull excellent slaughter traits is obtained, and polymorphism analysis is conducted to the segment for providing the molecular marker for marker assisted selection of the Chinese grassland red bull.

The invention belongs to the field of animal gene engineering. Seven promoters Six1-P, P1, P2, P3, P4, P5 and P6 with different lengths in the upstream of a specific expression gene of skeletal muscles in pigs are cloned from a pig genome. Nucleotide sequences of the promoters are shown in SEQ ID NO:1; 2; 3; 4; 5; 6; and 7. The lengths of the nucleotide sequences are respectively 1,692, 180, 530, 844, 1,143, 1,135 and 1,494bp. The activity analysis on promoter fragments with different lengths of a pig Six1 gene in three eukaryotic cells shows that the promoters of the pig Six1 gene are promoters which express the muscle specificity; except for the P1, other promoters P2, P3, P4, P5 and P6 all have the capacity of promoting gene expression; and in the promoters P2, P3, P4, P5 and P6, except for the promoter P2, other promoters all show the muscle specificity. The invention discloses the seven promoters, a method for preparing corresponding expression vectors of the seven promoters and identification of the promoter activity of the pig Six1 gene by using a dual-luciferase reporting system.

The present invention belongs to the field of animal gene engineering, and is especially the cloning and polymorphism application of goat's growth hormone (GH) gene. The present invention features that two DNA sequences of goat's GH gene as shown is obtained through cloning and two base mutations affecting goat's growth characters are detected. The present invention discloses two goat's GH gene sequences and two base mutational sites affecting goat's growth characters. The present invention also discloses the preparation process and application of the said genes, and provides new molecular markers for the auxiliary selection of goat's growth characters.

This invention relates to cloning and application of pig daily gain-related TEF-1 gene. The cDNA sequence of TEF-1 gene is shown in SEQ ID No.1. There is an A-G mutation at 93bp of SEQ ID No.1, which leads to BshN I-RFLP polymorphism. This invention also discloses a method for preparing pig daily gain-related TEF-1 gene, its primer design method, and the application of TEF-1 gene in molecular marker-assisted selection of pigs.

Expression vectors are disclosed that are comprised of (a) one or more silencer elements and conditionally inducible elements to form silencer-inducible regions and (b) promoters in operative linkage upstream of at least one expressed region. The expression vector thereby regulates expression of at least one downstream region by conditional silencing in which an expressed DNA region of a gene is transcribed to produce RNA transcripts, which may or may not be translated to produce polypeptides. Genetically engineered mammalian cells and non-human mammals can be made using such expression vectors through transfection and transgenesis techniques. Moreover, processes of making and using the aforementioned products are disclosed (e.g., the expression vector may be used diagnostically, therapeutically, or prophylactically).

The invention belongs to the technical field of animal gene engineering and relates to a construction method and a use of a duck enteritis virus bacterial artificial chromosome. Through cloning, a duck enteritis virus bacterial artificial chromosome pBAC-C-KCE plasmid is obtained, is preserved in the China center for type culture collection (CCTCC) and has an accession number of CCTCC NO: M2013377. The invention also discloses the use of the duck enteritis virus bacterial artificial chromosome pBAC-C-KCE in recombinant duck enteritis virus packaging.

This invention relates to preparation and application of orally administered recombinant DNA vaccine for accelerating animal growth, which Salmonella typhimurium CSO22/pGMCSF-SS (CCTCC M206141) is containing fusion expression plasmid pGMCSF-SS. Salmonella typhimurium CSO22/pGMCSF-SS is prepared by: cloning GMCSF, fusing with plasmid pcS/2SS containing somatostatin gene to obtain fusion expression plasmid pGMCSF-SS, and transforming Salmonella typhimurium. This invention also discloses the application of Salmonella typhimurium CSO22/pGMCSF-SS in orally administered recombinant DNA vaccine for accelerating animal growth.

The present invention belongs to the field of animal gene technology, and is especially one pig gene BTG1 related to its pork producing character and its cloning and application in auxiliary selection of pig's molecular marker. The present invention clones pig gene BTG1 related to its pork producing character with the sequence of SEQ ID No. 1, which has one A179-T179 base mutation in No. 179 bp and one C280-T280 base mutation in No. 280 bp to result in Psu1-RFLP polymorphism and Bsh1236I-RFLP polymorphism separately. The present invention also discloses the preparation process of the said gene and its primer, and provides new molecular marker for auxiliary selection of pig.